Study finds missed opportunities for targeted cancer treatments
statnews.com • • health
Key Points:
- A new study published in JAMA Network Open highlights that many patients with advanced cancers do not receive genomic testing, missing opportunities for targeted therapies.
- The research examined patients with five types of metastatic cancers and found that only about half underwent genetic sequencing.
- Disparities were noted, with lower rates of sequencing among patients with low income, those covered by Medicare or Medicaid, and individuals identifying as Black or Hispanic.
- The findings suggest the need for improved access and equity in genomic testing to ensure all eligible cancer patients can benefit from personalized treatment options.
